WASHINGTON, March 15 (UPI) -- The U.S. Food and Drug Administration is recommending stronger warnings be used for drugs prescribed to treat attention deficit hyperactivity disorder.
The FDA has been most concerned about reports of psychiatric and cardiovascular risks possibly linked with the drugs, The Wall Street Journal reported Wednesday. A meeting of outside medical experts, who will focus on the issue, is scheduled for next week.
The agency's ADHD psychiatric review team earlier this month said current labeling neither addresses the concerns nor does it "clearly state the importance of stopping drug therapy in any patient who develops hallucinations or other signs or symptoms of psychosis or mania during drug treatment of ADHD."
The FDA review found nearly 1,000 reports of psychosis or mania possibly linked to ADHD drugs -- including Adderall, Concerta, Ritalin and Strattera --were received between Jan. 1, 2000, and July 1, 2005.
Another FDA panel last month recommended stronger warnings concerning possible links between the ADHD drugs and heart attacks and strokes.
